Listen: Fake medical devices, real cancer drugs, & curious Ozempic effects
Why are fake medical devices more lucrative than real ones? Is Ozempic a neurological treatment?…
Category: Pharmaceuticals
.jpg)
STAT+: Coherus works with Mark Cuban to sell biosimilar Humira at steep discounts
In a bold move, Coherus BioSciences plans to sell a biosimilar version of Humira —…
STAT+: Pharmalittle: Pfizer touts study data for hemophilia drug; former Novartis execs cleared of bribery in Greece
Good morning, everyone, and how are you today? We are doing find, thank you, especially…
STAT+: U.K. unveils $800 million package to bolster life sciences amid concern over biopharma investments
LONDON — The U.K. government on Thursday unveiled an $800 million package to bolster the…
STAT+: Bristol drug reduces reliance on transfusions for people with chronic blood disorder
In a study reported Thursday, a medicine from Bristol Myers Squibb nearly doubled the treatment…
STAT+: Gilead and Teva defend antitrust claims that prices for HIV medicines were unfairly kept high
Amid concern that HIV prevention pills are not being widely taken by those at highest…
How Medicare’s Aduhelm decision revived old questions about new drugs
This article is adapted from the latest STAT Report: Decoding Medicare: 10 key coverage decisions…
Ketamine is comparable to ECT for patients with treatment-resistant depression, study shows
When seriously depressed patients don’t respond to antidepressants, the alternatives are limited. Now a new…
FDA budget battles, prisons’ sobering Covid response & BIO’s CEO search is on
You’re reading the web edition of D.C. Diagnosis. Sign up here to receive this newsletter…
STAT+: Achieve Life Sciences drug helps smokers quit in trial but would face stiff competition if approved
Seattle biotech Achieve Life Sciences on Tuesday announced an experimental drug meant to help people…
STAT+: Seagen criticized by shareholder advisory firm for ‘problematic’ executive compensation ahead of Pfizer acquisition
As Seagen prepares to be acquired by Pfizer, an investor advisory firm is raising concerns…
Novo says oral version of Ozempic leads to 15% weight loss
An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic…
STAT+: Novo Nordisk pauses ads for weight loss drug Wegovy as it struggles to meet demand
Novo Nordisk is pausing ads for its obesity drug Wegovy as it struggles to keep…
STAT+: FDA official offers insights into whether gene therapy makers could use common manufacturing process
WASHINGTON — A Food and Drug Administration official provided some insights this week into the…
Opinion: How I helped Pfizer think through the ethics of Viagra 25 years ago
Twenty-five years ago, 75-year-old Bob Dole — former Republican presidential candidate and U.S. senator from…
After new cluster, health officials warn mpox could resurge this summer
Federal health officials warned Thursday that there was a significant risk the mpox virus will…
STAT+: Supreme Court rules against Amgen in closely watched case over scope of patent claims
In a case that had the pharmaceutical industry on edge, the U.S. Supreme Court upheld…
Biden drug czar: ‘All options are on the table’ for expanding methadone access
WASHINGTON — The federal government is aggressively exploring ways to increase access to methadone, a…
STAT+: FTC widens probe into pharmacy benefit managers to include group purchasing organizations
The Federal Trade Commission is widening its probe into pharmacy benefit managers and their impact…
STAT+: Could an upcoming Supreme Court case make the FDA slower?
WASHINGTON — The Food and Drug Administration could take longer to write regulations and make…
STAT+: CVS Health to close clinical trial unit two years after launch
WOONSOCKET, R.I. — Two years after its launch, CVS Health is planning to close down…
STAT+: Biotech and pharma execs wrestle with the ‘nightmare’ of developing digital biomarkers
TARRYTOWN, N.Y. — As post-lunch drowsiness settled on an auditorium full of leaders from the…
STAT+: FTC move to block the Amgen-Horizon deal highlights concerns over negotiations with insurers
In an unexpected move, the U.S. Federal Trade Commission on Tuesday filed a lawsuit to…
AstraZeneca is third member to leave PhRMA in five months
WASHINGTON — AstraZeneca has decided to leave the brand drug lobbying powerhouse PhRMA halfway through…
Opinion: A breakthrough drug will require big changes for eye care doctors
Advancement in the science of eye care over the past 10 years has led to…
STAT+: U.S. Supreme Court declines to hear ‘skinny labeling’ case with implications for generic drug access
After months of anticipation, the U.S. Supreme Court declined to hear an appeal of a…
Opinion: Compounding pharmacies offer a fix for shortages of essential drugs
In the early days of the Covid pandemic, gravely ill patients began to fill America’s…
STAT+: AbbVie sues a behind-the-scenes company for exploiting its patient assistance program
AbbVie has filed a lawsuit against a behind-the-scenes company that helps health plan sponsors take…
STAT+: Senate panel passes a suite of drug pricing bills — but fails to advance one major PBM reform
WASHINGTON – The Senate health committee on Thursday passed a package of bills aimed at…
STAT+: Wyden decries ‘astonishingly low’ tax rates for pharma companies as he probes business maneuvers
Thanks to changes in tax law six years ago, several of the largest pharmaceutical companies…
STAT+: Telework helps FDA compete for scientists. What if it’s no longer an option?
WASHINGTON — The Food and Drug Administration needs to hire scores of in-demand scientists, and…
STAT+: Insulin makers, PBMs echo old finger-pointing in Senate hearing
A Senate hearing on high insulin costs billed as a blockbuster showdown with drugmakers and…
STAT+: Skin patch for toddlers with peanut allergy shows promising results in late-stage trial
Parents of kids who have peanut allergies have to practice constant vigilance, whether that means…
Black patients far less likely to receive key opioid addiction medication, study finds
Black people are far less likely than other Americans to receive buprenorphine, a key medication…
FDA panel votes in favor of the first-ever over-the-counter birth control pill
In a highly significant move, a panel of independent experts on Wednesday voted unanimously that…
STAT+: Brigham creates institute focused on immunology with record $100 million gift
Brigham and Women’s Hospital will launch a new institute focused on immunology and inflammation, thanks…
STAT+: In small study, weight loss drug boosts immune cells that help fight cancer
Drugs like Ozempic and Wegovy have become immensely popular for their ability to help people…
STAT+: What FDA mandate? Sun Pharma halts shipments from a plant with a troubled history
In a fresh sign of quality-control problems in the Indian pharmaceutical industry, the U.S. Food…
STAT+: Pharmalittle: Big pharma maps legal strategy against U.S. drug pricing reform; U.S. pharma layoffs continue to climb
Top of the morning to you, and a fine one it is. The sun is…
.jpg)
STAT+: Q&A: Sen. Sanders on insulin costs and his committee’s generic drug kerfuffle
WASHINGTON — Wednesday’s Senate hearing on high costs for insulin “is not the end” of…
Opinion: The IRA’s nonsensical distinction between small- and large-molecule drugs
Thanks to advances in science, notably the completion of the Human Genome Project 20 years…
STAT+: EQRX abandons business plan around drug pricing, cuts jobs and programs
EQRx, a company that aimed to lower drug prices by introducing inexpensive me-too medicines, said…
‘Robbing Peter to pay Paul’: Obesity experts debate risks of new weight loss drugs
Amid rising demand for drugs like Wegovy, Ozempic, and Mounjaro that can lead to significant…
Opinion: The amoxicillin shortage continues to force pediatricians and families to scramble
“So, you don’t have it in liquid form?” I asked. The answer, as usual, was…
To ease start of addiction treatment, doctors find surprise aid: ketamine
Ever since fentanyl came to dominate the U.S. illicit drug supply, doctors and patients have…
STAT+: Doudna talks cost, access issues looming over first CRISPR therapy
Jennifer Doudna may be just months away from seeing the first CRISPR-based therapy gain approval,…
STAT+: NIH grant recipients often fail to disclose agency support in patent applications
The National Institutes of Health may be the largest public funder of biomedical research in…
STAT+: Gilead foresees more growth in its HIV drugs
Gilead Sciences is famous — or perhaps, notorious — for its cure for hepatitis C….
Listen: Lilly’s Alzheimer’s success, a milestone FDA approval, & Moderna’s shrinking business
What’s the future of Alzheimer’s disease treatment? How do you pivot from a pandemic? And…
STAT+: A new list ranks large pharmaceutical companies by research and development
If you want a large pharmaceutical company to invent a new drug, your best bet…